IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
How can clinicians navigate emotionally complex patient interactions while maintaining empathy and trust? In this article, Mio Nakamura discusses communication approaches that may help strengthen patient relationships in dermatology settings.
Palmoplantar pustulosis (PPP) is a challenging inflammatory skin disease often misclassified as psoriasis. Dr. José-Manuel Carrascosa Carrillo shares clinical perspectives on PPP pathogenesis, diagnosis, and treatment, including biologics and JAK inhibitors.
This expert overview by IPC Junior Councilor María Julia Cura examines palmoplantar pustulosis as a distinct inflammatory disease with evolving therapeutic implications.
Expert dermatologist Professor Ryan discusses the link between psoriasis and malignancy, treatment safety, and best practices for patients with a history of or currently undergoing cancer treatment.
In this IPC Expert Insights article, Dr. Matthew Vesely examines cancer risk in psoriasis and provides insights on safe, effective patient treatment strategies.
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes and obesity, may offer a future treatment option for psoriasis and related inflammatory conditions.
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes and obesity, may offer a future treatment option for psoriasis and related inflammatory conditions.
This article examines the unique impact of psoriasis on individuals assigned female at birth, particularly during pregnancy and menopause, highlighting how hormonal changes influence disease management and the need for personalized, gender-sensitive care.
This article examines the unique impact of psoriasis on individuals assigned female at birth, particularly during pregnancy and menopause, highlighting how hormonal changes influence disease management and the need for personalized, gender-sensitive care.
IPC Councilor Ulrich Mrowietz, founder of the Psoriasis Center at University Medical Center Schleswig-Holstein, discusses psoriasis as a systemic disease with comorbidities like cardiovascular diseases and neuroinflammation. He emphasizes the importance of a multidisciplinary approach and ongoing research for better patient outcomes.
Psoriasis patients face the challenges of visible skin disease and the risks of developing related comorbidities. This article explores the connection between psoriasis and conditions like cardiovascular disease, metabolic syndrome, and inflammatory bowel disease. Discover how managing psoriasis effectively can help mitigate systemic health risks.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
